These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 8553769

  • 21. Cellular and humoral responses to microencapsulated Yersinia pestis subunit vaccines following oral delivery.
    Sharp GJ, Eyles JE, Williamson ED, Brown MR, Alpar HO.
    Biochem Soc Trans; 1997 May; 25(2):338S. PubMed ID: 9191383
    [No Abstract] [Full Text] [Related]

  • 22. Construction of defined F1 negative mutants of virulent Yersinia pestis.
    Worsham PL, Stein MP, Welkos SL.
    Contrib Microbiol Immunol; 1995 May; 13():325-8. PubMed ID: 8833864
    [No Abstract] [Full Text] [Related]

  • 23. [A method of assessing immunogenicity of preparations for plague prevention].
    Vasil'eva GI, Doroshenko EP, Kiseleva AK, Bespalova IA.
    Klin Lab Diagn; 1999 Mar; (3):37-9. PubMed ID: 10234932
    [Abstract] [Full Text] [Related]

  • 24. An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.
    Yamanaka H, Hoyt T, Bowen R, Yang X, Crist K, Golden S, Maddaloni M, Pascual DW.
    Vaccine; 2009 Jan 01; 27(1):80-7. PubMed ID: 18955097
    [Abstract] [Full Text] [Related]

  • 25. Effect of deletion of the lpxM gene on virulence and vaccine potential of Yersinia pestis in mice.
    Anisimov AP, Shaikhutdinova RZ, Pan'kina LN, Feodorova VA, Savostina EP, Bystrova OV, Lindner B, Mokrievich AN, Bakhteeva IV, Titareva GM, Dentovskaya SV, Kocharova NA, Senchenkova SN, Holst O, Devdariani ZL, Popov YA, Pier GB, Knirel YA.
    J Med Microbiol; 2007 Apr 01; 56(Pt 4):443-453. PubMed ID: 17374882
    [Abstract] [Full Text] [Related]

  • 26. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response.
    Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, Conlon JE, Fukase K, Kusumoto S, Sweet C, Miyake K, Akira S, Cotter RJ, Goguen JD, Lien E.
    Nat Immunol; 2006 Oct 01; 7(10):1066-73. PubMed ID: 16980981
    [Abstract] [Full Text] [Related]

  • 27. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E.
    Vaccine; 2008 Mar 20; 26(13):1616-25. PubMed ID: 18304706
    [Abstract] [Full Text] [Related]

  • 28. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs.
    Feodorova VA, Pan'kina LN, Savostina EP, Sayapina LV, Motin VL, Dentovskaya SV, Shaikhutdinova RZ, Ivanov SA, Lindner B, Kondakova AN, Bystrova OV, Kocharova NA, Senchenkova SN, Holst O, Pier GB, Knirel YA, Anisimov AP.
    Vaccine; 2007 Nov 01; 25(44):7620-8. PubMed ID: 17913308
    [Abstract] [Full Text] [Related]

  • 29. Yersinia pestis YadC: a novel vaccine candidate against plague.
    Murphy BS, Wulff CR, Garvy BA, Straley SC.
    Adv Exp Med Biol; 2007 Nov 01; 603():400-14. PubMed ID: 17966436
    [Abstract] [Full Text] [Related]

  • 30. [Prophylactic use of ceftriaxone in combination with F I antigen immunization in studies on uninbred albino mice infected by Yersinia pestis. Antiplague immunity development].
    Ryzhko IV, Moldavan IA, Tsuraeva RI, Shcherbaniuk AI.
    Antibiot Khimioter; 2006 Nov 01; 51(9-10):8-12. PubMed ID: 18030785
    [Abstract] [Full Text] [Related]

  • 31. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM, Sambir M, D'Arco C, Peters LA, Seegers JF, Mayer L, McCormick AA, Dattwyler RJ.
    Vaccine; 2016 Nov 11; 34(47):5768-5776. PubMed ID: 27745954
    [Abstract] [Full Text] [Related]

  • 32. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.
    Levy Y, Flashner Y, Tidhar A, Zauberman A, Aftalion M, Lazar S, Gur D, Shafferman A, Mamroud E.
    Vaccine; 2011 Sep 16; 29(40):6866-73. PubMed ID: 21803090
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L, Manocha M, Sridevi K, Shashikiran D, Rayanade R, Rao DN.
    FEMS Immunol Med Microbiol; 2003 Oct 15; 38(3):215-29. PubMed ID: 14522457
    [Abstract] [Full Text] [Related]

  • 35. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.
    Goodin JL, Nellis DF, Powell BS, Vyas VV, Enama JT, Wang LC, Clark PK, Giardina SL, Adamovicz JJ, Michiel DF.
    Protein Expr Purif; 2007 May 15; 53(1):63-79. PubMed ID: 17293124
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW.
    Microb Pathog; 1997 Sep 15; 23(3):167-79. PubMed ID: 9281474
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.